Topics

Articles

Balancing innovation focus with optimized decision-making.


Biotech’s Achilles’ Heel

ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025. 

BioMarin Adjusts Sales Plan for Severe Hemophilia A Gene Therapy

Per the deal, DKSH inherits the specialty pharma company’s Asia-Pacific medication portfolio. 

DKSH, Kyowa Kirin Sign Strategic Partnership 

In deal that has the potential to reach $1.1 billion, Otsuka aims to grow its drug pipeline, specifically in the field of rare and autoimmune diseases. 

Otsuka Pharmaceutical to Purchase Jnana Therapeutics 

The parties’ combined portfolio help tackle the rising demand for advanced cell and gene therapies.  

MilliporeSigma Finalizes Mirus Bio Deal

Gallagher’s 2024 US Physical & Emotional Wellbeing Report outlines ways to meeting evolving needs in the workforce. 

Mental Health, Rising Healthcare Costs Headline Employer and Employee Concerns 

The partnership—which features a $150 million investment—is also centered around vaccine development in the respiratory and immunology space.  


GSK, Flagship Pioneering Collaborate on Novel Medicine Discovery

The acquisition provides Ardian with greater insight into the life science industry.

Ardian Buys Majority Stake in Masco Group 

The parties will continue to create new candidate therapies for the treatment of a severe form of TUBB4A leukodystrophy.

SynaptixBio, Evotec Extend Research and Development Collaboration

The deal exponentially grows the CDMO’s biopharma capabilities.

Business and Finance